Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion

QR Code

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion

Tumor extracellular matrix has been associated with cancer progression, therapy resistance and immune suppression. Here, the authors show that collagen generates resistance to PD-1/PD-L1 immunotherapy by upregulating LAIR1 expression and downstream signaling, leading to increased CD8+ T cell exhaust...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	David H. Peng, Bertha Leticia Rodriguez, Lixia Diao, Limo Chen, Jing Wang, Lauren A. Byers, Ying Wei, Harold A. Chapman, Mitsuo Yamauchi, Carmen Behrens, Gabriela Raso, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Ignacio I. Wistuba, Jonathan M. Kurie, Don L. Gibbons
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2020
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/219973ddbc6547bdba9bd0531b756cc7
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
par: Alexander Roberts, et autres
Publié: (2021)

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
par: David H. Peng, et autres
Publié: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
par: Hyun Tae Lee, et autres
Publié: (2017)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
par: González-Cao M, et autres
Publié: (2015)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
par: LAI Yanliang, et autres
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)

PD-L1 expression in angiomatoid fibrous histiocytoma
par: Joshua Byers, et autres
Publié: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
par: Grecea M, et autres
Publié: (2021)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
par: Dinoop Ravindran Menon, et autres
Publié: (2021)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
par: Min Yu, et autres
Publié: (2021)

Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium
par: Masayuki Nakajima, et autres
Publié: (2021)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publié: (2021)

PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity
par: Doumet Georges Helou, et autres
Publié: (2020)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
par: Nitin Roper, et autres
Publié: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
par: Olga V. Kovaleva, et autres
Publié: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
par: Miao Wang, et autres
Publié: (2021)

Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression
par: Myoungsun Son, et autres
Publié: (2017)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
par: Lai CY, et autres
Publié: (2021)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
par: KE Ping, et autres
Publié: (2021)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
par: Sarah J. Dart, et autres
Publié: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
par: Yixi Zhang, et autres
Publié: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
par: Chunyi Shen, et autres
Publié: (2021)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
par: Yang Hu, et autres
Publié: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
par: Laura Jimbu, et autres
Publié: (2021)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
par: Grégoire de Streel, et autres
Publié: (2020)

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
par: A. N. Niemeijer, et autres
Publié: (2018)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
par: Peiyi Xie, et autres
Publié: (2021)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
par: Keller J Toral, et autres
Publié: (2021)

A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells
par: Torben Knuschke, et autres
Publié: (2021)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
par: Christine Bekos, et autres
Publié: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
par: Jiang Q, et autres
Publié: (2021)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
par: Kensuke Kojima, et autres
Publié: (2021)

Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs
par: Kai Xu, et autres
Publié: (2021)

Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion
par: Cheng Sun, et autres
Publié: (2018)

PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma
par: Longxiang Tao, et autres
Publié: (2021)

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
par: Yoshihisa Shimada, et autres
Publié: (2021)

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
par: Victoria Klepsch, et autres
Publié: (2018)

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
par: Neta Rosenzweig, et autres
Publié: (2019)

Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy
par: Christina Polasky, et autres
Publié: (2021)